Download PDF
Laryngorhinootologie 2017; 96(09): 590-596
DOI: 10.1055/s-0043-109180
Übersicht

Molekulare Pathogenese von Schilddrüsenknoten – Bedeutung für die klinische Versorgung

Molecular Pathogenesis of Thyroid Nodules: Relevance for Clinical Care
D. Führer 
1   Klinik für Endokrinologie und Stoffwechselerkrankungen, Zentrallabor – Bereich Forschung und Lehre, Endokrines Tumorzentrum am WTZ und ENETS Center of Excellence, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen
,
T. Musholt
2   Sektion Endokrine Chirurgie, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsmedizin Mainz, Mainz
,
K. W. Schmid
3   Institut für Pathologie, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Schilddrüsenknoten stellen heterogene Tumore dar, mit unterschiedlichen molekularen Signaturen. Während benigne Schilddrüsenknoten poly- oder monoklonalen Tumoren entsprechen, sind Schilddrüsenkarzinome monoklonale und damit „echte“ Neoplasien. Ursächlich für die Neoplasien sind somatische Mutationen, welche zur konstitutiven Aktivierung spezifischer Signalkaskaden führen und den jeweiligen histologischen, teilweise auch den funktionellen Phänotyp des Schilddrüsentumors bestimmen. Eine Dedifferenzierung von Schilddrüsenkarzinomen geht mit dem Auftreten weiterer Mutationen in den Tumoren einher. Die Mutationslast der Schilddrüsenkarzinome korreliert mit deren biologischem Verhalten.

Im klinischen Alltag kann die Kenntnis der ursächlichen somatischen Mutation in der zytologischen Differenzialdiagnose helfen. In der prognostischen Einschätzung von Schilddrüsentumoren hat der Nachweis von klassischen Onkogenmutationen (BRAF, RAS) wenig Relevanz. Andere genetische Veränderungen, insbesondere TERT Promoter Mutationen, die mit zunehmender Häufigkeit in fortgeschrittenen SD-Karzinomen auftreten, haben wahrscheinlich eine prognostische Bedeutung. Von großer Relevanz ist die molekulare Signatur jedoch für die Entwicklung und Anwendung passgenauer „zielgerichteter“ Therapien bei fortgeschrittenen Karzinomen (radioiodrefraktäres DTC, PDTC und ATC, metastasiertes medulläres Karzinom). Hierfür gibt es aus klinischen Studien sowie Einzelfallberichten zunehmend Hinweise, die das Konzept der „Oncogen-Addiction“ als pathogenetisch relevanten Mechanismus der SD-Tumorigenese und Karzinogenese unterstreichen.

Abstract

Thyroid nodules represent heterogeneous tumors with distinct molecular signatures. While benign thyroid nodules correspond to poly- or monoclonal tumors, thyroid carcinomas are monoclonal and thus “real” neoplasms. These are caused by somatic mutations that lead to the constitutive activation of specific signaling cascades and determine the corresponding histology and also partly the functional phenotype of the thyroid tumor. Dedifferentiation of thyroid carcinomas is accompanied by the occurrence of additional mutations in the tumors. The mutation load of thyroid carcinomas correlates with their biological behavior.

In clinical practice, detection of somatic mutations can help in the cytological differential diagnosis. In the prognostic assessment of thyroid tumors, proof of classical oncogene mutations (BRAF, RAS) has little relevance. Other genetic alterations, especially TERT promoter mutations that occur with increasing frequency in advanced thyroid carcinomas, probably have a prognostic significance. The molecular signature, however, is of great relevance for the development and application of targeted therapies in advanced carcinomas (radioactive iodine-refractory DTC, PDTC and ATC, metastatic medullary carcinoma). For this, there is increasing evidence from clinical studies and case reports that underline the concept of “oncogene addiction” as a pathogenetically relevant mechanism of thyroid tumorigenesis and carcinogenesis.

Schlüsselwörter

Schilddrüsenkarzinom - somatische Mutation - TERT Promoter Mutation - molekulare Signatur - Oncogen-Addiction

Key words

thyroid carcinoma - somatic mutation - TERT promoter mutation - molecular signature - oncogene addiction


Publication History

Article published online:
07 September 2017

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Agrawal N, Jiao Y, Sausen M. et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013; 98: E364-E369
    CrossrefPubMedGoogle Scholar
  • 2 Ameziane-El-Hassani 1 R, Talbot 2 M, de Souza Dos Santos 3 MC. et al NADPH oxidase DUOX1 promotes long-term persistence of oxidative stress after an exposure to irradiation. Proc Natl Acad Sci U S A 2015; 112: 5051-5056
    CrossrefPubMedGoogle Scholar
  • 3 Cancer Genome Atlas Research N . Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159: 676-690
    CrossrefPubMedGoogle Scholar
  • 4 Cheung L, Messina M, Gill A. et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2003; 88: 354-357
    CrossrefPubMedGoogle Scholar
  • 5 Driessens N, Versteyhe S, Ghaddhab C. et al. Hydrogen peroxide induces DNA single- and double-strand breaks in thyroid cells and is therefore a potential mutagen for this organ. Endocr Relat Cancer 2009; 16: 845-856
    CrossrefPubMedGoogle Scholar
  • 6 Dummer R, Schadendorf D, Ascierto PA. et al. Integrating first-line treatment options into clinical practice: what’s new in advanced melanoma?. Melanoma Res 2015; 25: 461-469
    CrossrefPubMedGoogle Scholar
  • 7 Elisei R, Alevizaki M, Conte-Devolx B. et al. 2012 European Thyroid Association Guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J 2012; 1: 216-231
    CrossrefPubMedGoogle Scholar
  • 8 Elisei R, Cosci B, Romei C. et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008; 93: 682-687
    CrossrefPubMedGoogle Scholar
  • 9 Falchook GS, Millward M, Hong D. et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 2015; 25: 71-77
    CrossrefPubMedGoogle Scholar
  • 10 Führer D, Bockisch A, Schmid KW. Euthyroid goiter with and without nodules – diagnosis and treatment. Dtsch Arztebl Int 2012; 109: 506-515
    PubMedGoogle Scholar
  • 11 Führer D, Gimm O, Brabant G. et al Schilddrüsenkarzinom. Rationelle Diagnostik und Therapie in Endokrinologie, Diabetologie und Stoffwechsel. Lehnert HH. Thieme Verlag; 3. Auflage. . 2014
    Google Scholar
  • 12 Führer D, Holzapfel HP, Wonerow P. et al Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 1997; 82: 3885-3891
    PubMedGoogle Scholar
  • 13 Führer D, Schmid KW. Benign thyroid nodule or thyroid cancer?. Internist (Berl) 2010; 51: 611-619
    PubMedGoogle Scholar
  • 14 Godbert Y, Henriques de Figueiredo B, Bonichon F. et al Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma. J Clin Oncol 2015; 33: e84-e87
    CrossrefPubMedGoogle Scholar
  • 15 Karger S, Krause K, Engelhardt C. et al. Distinct pattern of oxidative DNA damage and DNA repair in follicular thyroid tumours. J Mol Endocrinol 2012; 48: 193-202
    CrossrefPubMedGoogle Scholar
  • 16 Karger S, Weidinger C, Krause K. et al. FOXO3a: a novel player in thyroid carcinogenesis?. Endocr Relat Cancer 2009; 16: 189-199
    CrossrefPubMedGoogle Scholar
  • 17 Kelly LM, Barila G, Liu P. et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A 2014; 111: 4233-4238
    CrossrefPubMedGoogle Scholar
  • 18 Kim KB, Cabanillas ME, Lazar AJ. et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 2013; 23: 1277-1283
    CrossrefPubMedGoogle Scholar
  • 19 Kimura ET, Nikiforova MN, Zhu Z. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-1457
    PubMedGoogle Scholar
  • 20 Kimura T, Van Keymeulen A, Golstein J. et al. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 2001; 22: 631-656
    CrossrefPubMedGoogle Scholar
  • 21 Kleinau 1 G, Neumann S, Grüters A. et al. Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev 2013; 34: 691-724
    CrossrefPubMedGoogle Scholar
  • 22 Krause K, Prawitt S, Eszlinger M. et al. Dissecting molecular events in thyroid neoplasia provides evidence for distinct evolution of follicular thyroid adenoma and carcinoma. Am J Pathol 2011; 179: 3066-3074
    CrossrefPubMedGoogle Scholar
  • 23 Krohn K, Führer D, Bayer Y. et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 2005; 26: 504-524
    CrossrefPubMedGoogle Scholar
  • 24 Krohn K, Führer D, Holzapfel HP. et al. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J Clin Endocrinol Metab 1998; 83: 130-134
    CrossrefPubMedGoogle Scholar
  • 25 Kunstman JW, Juhlin CC, Goh G. et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 2015; 24: 2318-2312
    CrossrefPubMedGoogle Scholar
  • 26 Landa I, Ibrahimpasic T, Boucai L. et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest; 2016
    PubMedGoogle Scholar
  • 27 Latteyer S, Tiedje V, König K. et al. Next generation sequencing mutation profiling reveals novel putative tumor candidates in anaplastic thyroid cancer. Endocrine 2016, in press.
    PubMedGoogle Scholar
  • 28 Liu T, Wang N, Cao J. et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 2014; 33: 4978-4984
    CrossrefPubMedGoogle Scholar
  • 29 Maier J, van Steeg H, van Oostrom C. et al. Deoxyribonucleic acid damage and spontaneous mutagenesis in the thyroid gland of rats and mice. Endocrinology 2006; 147: 3391-3397 Epub 2006 Apr 20.
    CrossrefPubMedGoogle Scholar
  • 30 Melo M, da Rocha AG, Vinagre J. et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 2014; 99: E754-E765
    CrossrefPubMedGoogle Scholar
  • 31 Müller K, Führer D, Mittag J. et al TSH compensates thyroid-specific IGF-I receptor knockout and causes papillary thyroid hyperplasia. Mol Endocrinol 2011; 25: 1867-1879
    CrossrefPubMedGoogle Scholar
  • 32 Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 2011; 71: 4403-4411
    CrossrefPubMedGoogle Scholar
  • 33 Nikiforova MN, Lynch RA, Biddinger PW. et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003; 88: 2318-2326
    CrossrefPubMedGoogle Scholar
  • 34 Nikiforova MN, Stringer JR, Blough R. et al. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 2000; 290: 138-141
    CrossrefPubMedGoogle Scholar
  • 35 Ricarte-Filho JC, Ryder M, Chitale DA. et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009; 69: 4885-4893
    CrossrefPubMedGoogle Scholar
  • 36 Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 2013; 368: 684-685
    CrossrefPubMedGoogle Scholar
  • 37 Shi X, Liu R, Qu S. et al. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab 2015; 100: E632-E637
    CrossrefPubMedGoogle Scholar
  • 38 Smith N, Nucera C. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab 2015; 100: 35-42
    CrossrefPubMedGoogle Scholar
  • 39 Soares P, Trovisco V, Rocha AS. et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22: 4578-4580
    CrossrefPubMedGoogle Scholar
  • 40 Studer H, Derwahl M. Mechanisms of nonneoplastic endocrine hyperplasia–a changing concept: a review focused on the thyroid gland. Endocr Rev 1995; 16: 411-426
    PubMedGoogle Scholar
  • 41 Tiedje V, Kroiss M, Dralle H. et al. Protokoll zur multimodalen Therapie des anaplastischen Schilddrüsenkarzinoms. Endokrinologie Informationen. 2015
    PubMedGoogle Scholar
  • 42 Tiedje V, Ting S, Dralle H. et al. Medullary thyroid carcinoma. Internist (Berl) 2015; 56: 1019-1031
    PubMedGoogle Scholar
  • 43 Tiedje V, Ting S, Walter RF. et al. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients. ur J Endocrinol. 2016
    PubMedGoogle Scholar
  • 44 Ting S, Schmid ST, Synoracki S. et al. Thyroid C cells and their pathology: Part 1: normal C cells, - C cell hyperplasia, - precursor of familial medullary thyroid carcinoma]. Pathologe 2015; 36: 571
    PubMedGoogle Scholar
  • 45 Versteyhe S, Driessens N, Ghaddhab C. et al. Comparative analysis of the thyrocytes and T cells: responses to H2O2 and radiation reveals an H2O2-induced antioxidant transcriptional program in thyrocytes. J Clin Endocrinol Metab 2013; 98: E1645-E1654
    CrossrefPubMedGoogle Scholar
  • 46 Wagle N, Grabiner BC, Van Allen EM. et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014; 371: 1426-1433
    CrossrefPubMedGoogle Scholar
  • 47 Wells Jr SA, Asa SL, Dralle H. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25: 567-610
    CrossrefPubMedGoogle Scholar
  • 48 Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013; 381: 1058-1069
    CrossrefPubMedGoogle Scholar
  • 49 Xing M, Liu R, Liu X. et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014; 32: 2718-2726
    CrossrefPubMedGoogle Scholar
  • 50 Zhang Y, Yu J, Lee C. et al. Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein. Oncotarget 2015; 6: 40418-40432
    CrossrefPubMedGoogle Scholar